LL-37 (Cathelicidin) vs TB-500
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →TB-500
Thymosin Beta-4 (TB-500) is a naturally occurring peptide present in almost all human and animal cells. It plays a crucial role in tissue repair and regeneration.
Full details →Side-by-Side Comparison
| Aspect | LL-37 (Cathelicidin) | TB-500 |
|---|---|---|
| Mechanism | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. | TB-500 promotes cell migration and differentiation, regulates actin (a cell-building protein), and reduces inflammation. It supports the formation of new blood vessels and wound healing. |
| Typical Dosage | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. | Research protocols typically use 2-2.5mg twice weekly during the loading phase, followed by maintenance dosing of 2mg every 2 weeks. |
| Administration | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. | Administered via subcutaneous or intramuscular injection. Some protocols suggest injection near injury sites. |
| Side Effects | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. | May cause temporary fatigue, headache, or localized irritation at injection sites. |
| Best For |
What They Have in Common
Both LL-37 (Cathelicidin) and TB-500 are commonly used for: